Bortezomib (PS-341)

製品コードS1013 別名:LDP-341, MLM341

Bortezomib (PS-341)化学構造

分子量(MW):384.24

Bortezomib (PS-341) is a potent 20S proteasome inhibitor with Ki of 0.6 nM. It exhibits favorable selectivity towards tumor cells over normal cells.

サイズ 価格(税別)  
JPY 11620.00
JPY 44820.00
JPY 111220.00

文献中の使用例(148)

カスタマーフィードバック(25)

  • Immunoblot analysis of cell lysates from the indicated cell lines treated with GNE-6776 (2 μ M for 18 h), either alone or in combination with a UAE1 inhibitor MLN-7243 (5 μ M for 45 min) or the proteasome inhibitor bortezomib (5 μ M for 45 min) as indicated.

    Nature, 2017, 550(7677):534-538. Bortezomib (PS-341) purchased from Selleck.

    Indisulam dependent degradation of RBM39 can be blocked by bortezomib, a proteasome inhibitor. Cells were pretreated with indicated concentrations of bortezomib for 2 hours, followed by 6 hours of treatment with 2 μM indisulam. The effect of bortezomib is attenuated in a bortezomib resistant cell line.

    Science, 2017, eaal3755. Bortezomib (PS-341) purchased from Selleck.

  • Wild-type mice fed as indicated were injected with vehicle (10% DMSO, pH 7.4 PBS) or bortezomib (5 mg/kg bodyweight). Livers were collected 16 hr later for quantitative PCR analysis of indicated genes (n = 4–5). *p < 0.05 bortezomib effect and #p < 0.05 Chol-Diet effect by two-way ANOVA.

    Cell, 2017, 171(5):1094-1109. Bortezomib (PS-341) purchased from Selleck.

    Effect of different proteasome inhibitors on dysferlin expression and on membrane resealing in cultured primary myoblasts. Primary myoblasts from patient 2 harboring a homozygous Arg555Trp DYSF mutation that were treated with the indicated amounts of bortezomib for 24 hours. Western blots of protein extracts were stained with anti-dysferlin antibodies and with anti–a-tubulin antibody as loading control.

    Sci Transl Med 2015 6(250), 250ra112. Bortezomib (PS-341) purchased from Selleck.

  • Pharmacologic inhibition of the proteasome blocks proplatelet formation in murine and human megakaryocytes. Human megakaryocytes were pretreated with vehicle or bortezomib, and megakaryocytes producing proplatelets (PP) were examined. Shown are representative transmission images and representative confocal images with wheat germ agglutinin (WGA; red) and phalloidin (green) staining. Scale bars: 50 um.

    J Clin Invest 2014 124(9), 3757-66. Bortezomib (PS-341) purchased from Selleck.

    Effects of NF-kB inhibition on cell proliferation and apoptosis in Foxp3cKO prostate. A. Top left panels: Representative H&E staining of PIN lesions in ventral prostates of 60-week-old PBS- or bortezomib-treated Foxp3cKO littermates. Scale bar, 50 祄. Right graph: Quantification of Ki67-positive cells identified by IHC analysis (bottom left panels) as a measure of cell proliferation, performed with Scion Image software. Horizontal lines represent the average values. The p value was determined by two-tailed t test. B. Representative western blots showing p65 and nuclear p65 (N-p65) expression in prostates at 12 hours after LPS injection in 45-week-old PBS- or bortezomib-treated mice. C. Quantification of Bcl2l1 and Traf1/2 mRNA expression as a percentage of Hprt expression measured in microdissected mouse prostate epithelial cells by qPCR at 12 hours after LPS injection in 45-week-old PBS- or bortezomib-treated mice. Horizontal lines represent the average values. The p values were determined by two-tailed t test. D. Left panels: Representative images of TUNEL assays performed on prostates from PBS- or bortezomib-treated mice at 60 weeks of age. Insets show the apoptotic cells (green) in prostate glands. Scale bar, 100 祄. Right graph: Quantification of apoptotic cells in the ventral and dorsolateral prostates of PBS- or bortezomib-treated mice at 45 and 60 weeks of age. Horizontal lines represent the average values. The p value was determined by two-tailed t test. cKO, PB4-Cre4+Foxp3flox/y; wks, weeks; B/P, ratio of the mean value from bortezomib-treated mice to the mean value in PBS-treated mice. All experiments were repeated two times. Wks, weeks.

    Cancer Res 2015 75(8), 1714-24. Bortezomib (PS-341) purchased from Selleck.

  • Immunofluorescence showing HDAC4 localization in mouse primary osteoblasts treated with vehicle or PTH alone or in the presence of bortezomib. Primary osteoblasts treated with vehicle, PTH, or PTH plus bortezomib for 2 h using anti-HDAC4 and anti-b-actin antibodies.

    J Cell Biol 2014 205(6), 771-80. Bortezomib (PS-341) purchased from Selleck.

    Inhibition of proteasome and lysosome or silencing of VCP and co-factors lead to the accumulation of OP-puro-labeled DRIPs adjacent to or within SGs. HeLa cells were co-treated for 45 min with OP-puro and arsenite (Ars.); where indicated, cells were pretreated with bortezomib (Bort.) overnight and/or ammonium chloride (NH4Cl) for 2 h 15 min. Cells were fixed and labeled with Alexa594-Azide and anti-TIA-1.

    Cell Death Differ 2014 21(12), 1838-51. Bortezomib (PS-341) purchased from Selleck.

  • Immunofluorescence analysis for Ser536 p-NF-κB cellular localization of RS4;11cells treated with CX-4945 (5 μM) and bortezomib (2.5 nM) either alone or in combination. Cells were treated, collected at 22 h and reacted with an antibody to Ser536 p-NF-κB which was revealed by a Cy3-conjugated secondary antibody. DAPI was used to label nuclei.

    Oncotarget, 2015, 51: S659-S660. Bortezomib (PS-341) purchased from Selleck.

    Control wild-type and Fmn2–/–oocytes observed at different stages of meiotic maturation [prophase I (Pro I), NEBD, 3 hours and 8 hours after NEBD] using anti-Fmn2. wt + Bortezo, wild-type oocytes treated with 0.1μM Bortezomib for 90 minutes before fixation. All oocytes were observed using the same settings and the images treated the same way (three independent experiments). Red arrows indicate cortical labeling. Scale bar: 10μm.

    Development 2011 138, 2903-2908. Bortezomib (PS-341) purchased from Selleck.

  • Cell viability of HCT116 cells treated with a single drug or with the addition of leucovorin.

    Sci Rep, 2017, 7(1):682. Bortezomib (PS-341) purchased from Selleck.

    (B–C) LNCaP (B) and LNCaP-AI (C) cells were transiently transfected with sPLA2-IIa(-800)-Luc (0.5 μg). The cells were then treated with Erlotinib (20 μM), Gefitinib (20 μM), Lapatinib (20 μM), CI-1033 (8 μM), LY294002 (20 μM) and Bortezomib (20 μM) without or with EGF (100 ng/ml) for 24 h. Luciferase assay was performed according to a standard protocol with Renilla luciferase as an internal control. Data are presented as the mean (±SD) of duplicate values of a representative experiment that was independently repeated for five times.

    Carcinogenesis 2010 31, 1948–1955. Bortezomib (PS-341) purchased from Selleck.

  • LNCaP-AI cells were starved in 1% stripped medium for 24 h. The cells were then treated with Erlotinib (20 μM), Gefitinib (20 μM), Lapatinib (20 μM), CI-1033 (8 μM), LY294002 (20 μM) and Bortezomib (20 μM) for 24 h. Cell culture medium was collected from each sample and subjected to ELISA for sPLA2-IIa. The condition medium samples were diluted 10 times for ELISA. Average of duplicate samples was converted to nanogram per milliliter against standard curve. The data represent one of five repeated experiments.

     

     

    Carcinogenesis 2010 31, 1948–1955. Bortezomib (PS-341) purchased from Selleck.

    PS-341 impairs FPV replication in A549 cells. (A and B)A549 cells were either pretreated for 1 h with different concentrations of PS-341 or with solvent only or were left untreated. Then, cells were infected with FPV at an MOI of 0.001 (A) or 0.05 (B). After virus inoculation cells were posttreated with different concentrations of PS-341. (A) At 24 h p.i. supernatants were obtained and progeny virus titers were measured by standard plaque assay. (B)Proteasome activity and the ability of PS-341 to inhibit the proteasome was determined 24 h p.i. (C) A549 cells were pretreated with 50 nM PS-341 or solvent or left untreated for 1 h. Afterwards cells were infected with FPV at an MOI of 0.0005. Subsequent to virus inoculation cells were posttreated with 50 nM PS-341 or solvent or left untreated. After the indicated times p.i.supernatants were obtained and progeny virus titers were determined by standard plaque assay. Arrow bars in all experiments represent standard deviations of three independent experiments.

    J Virol 2010 84, 9439–9451. Bortezomib (PS-341) purchased from Selleck.

  • Early steps of viral replication within the first replication cycle are affected. (A) For time-of-addition kinetics analysis, A549 cells were either left untreated or were pretreated for 10 h or 1 h with 50 nM PS-341 before infection and additionally posttreated after infection. Cells were infected with FPV at an MOI of 0.005. After virus inoculation cells were posttreated with 50 nM PS-341. Then the proteasome inhibitor was added after virus inoculation (10 h, 1 h, and 30 min) or it was added at the different times p.i. as indicated (1 h, 2 h, 4 h, 6 h, and 8 h; cells were not pretreated before infection). At 9 h p.i. supernatants were obtained and progeny virus titers were determined by standard plaque assay. Shown is one representative experiment out of three independent experiments. (B) A549 cells were pretreated with 50 nM PS-341 or left untreated for 1 h. Afterwards cells were infected with avian FPV or human PR8 at an MOI of 1. Subsequent to virus inoculation cells were posttreated with 50 nM PS-341 or left untreated. After the indicated times p.i. cells were lysed and analyzed by Western blotting for accumulation of viral proteins polymerase PB1 and matrix protein M1. Cellular protein ERK2 served as a control to demonstrate equal amounts of protein loading. Shown is one representative blot out of three independent experiments.

     

     

    J Virol 2010 84, 9439–9451. Bortezomib (PS-341) purchased from Selleck.

    A549 cells were treated with PS-341 at 50 nM for the indicated times or left untreated. Western blotting was performed with total cell lysates, using phospho-specific antibodies against JNK and the transcription factors c-Jun and ATF-2 or loading controls, respectively.

     

     

    J Virol 2010 84, 9439–9451. Bortezomib (PS-341) purchased from Selleck.

  • Western blot of extracts of infected cells treated with different proteasome inhibitors at different concentrations, reacted with the indicated antibodies. p53 was used to monitor proteasome inhibition, and actin was used as a loading control.

     

     

    J Virol 2011 85, 2781–2792. Bortezomib (PS-341) purchased from Selleck.

    Time window treatment with proteasome inhibitors. (A) Scheme of the experiment performed with MA104 cells exposed to virus (OSU; MOI, 3) for 1 h and analyzed at the starting point and endpoint of the indicated time window treatments with DMSO, MG132, or bortezomib. (B) Western blot of cellular lysates derived from cells infected for the indicated time periods and treated with the proteasome inhibitors or DMSO. NI, noninfected cells. Blots were reacted with the indicated antibodies; p53 was used to monitor proteasome inhibition, and actin was used as a loading control.

    J Virol 2011 85, 2781–2792. Bortezomib (PS-341) purchased from Selleck.

  • Fluorescence analysis of viroplasm formation on NSP5-EGFP cells infected with rotavirus (OSU; MOI, 3) and treated or not treated with MG132 (10 M) or bortezomib (10 M) at different times p.i., as indicated. Cells were analyzed at the starting points (1 h, 3 h, 5 h, 7 h) and endpoints (9 h) of the inhibitor’s window treatment.

     

     

    J Virol 2011 85, 2781–2792. Bortezomib (PS-341) purchased from Selleck.

    Quantification of the accumulation of viroplasms in infected NSP5 -EGFP/MA104 cells. At different times p.i., cells were treated for 4 h with DMSO or the indicated proteasome inhibitor and the number of viroplasms/cell was quantified at the starting (1 h, 3 h, 5 h; white bars) and endpoints (5 h, 7 h, 9 h) of treatment.

     

     

    J Virol 2011 85, 2781–2792. Bortezomib (PS-341) purchased from Selleck.

  • The stable cell line HepAD38 was incubated for 18 h in the presence of the indicated amount of Bortezomib. The medium was removed and replaced by medium containing Bortezomib dissolved in PBS. In case of the control cells the same amount of PBS was added to the medium. 4 h later this procedure was repeated and again 14 h later the supernatant was collected. The amount of viral particles was quantified by real time PCR. HBV-genome quantification was done using COBAS® AmpliPrep/COBAS® TaqMan® HBV test (Roche Diagnostics GmbH, Mannheim, Germany) according to the manufacturer’s instructions. The assay shows relative values (the value for untreated control cells was arbitrarily set as 1) that are based on three independent experiments. The cell viability was analyzed by MTT assays. For does up to 50 nM no significant effect on cell viability was observed within 18h, for 100 nM the proportion of metabolically active cells was reduced to 83%.

    J Biol Chem 2010 285, 41074-41086. Bortezomib (PS-341) purchased from Selleck.

    HLC-1 cells were treated with IFN-gamma (30 ng/ml) and Bortezomib (0-10 nM) for 3 h. After washing with PBS, the cells were cultured for another 45 h in the fresh medium. After 48 h incubation, PD-L1 expression was analysed by flow cytometry (n =3).

    Int Immunopharmacol, 2018, 54:39-45. Bortezomib (PS-341) purchased from Selleck.

  • Proteasome inhibition effect on biotinylation of MHC-Iα. (a) WB-ra of cellular extracts of HEK293 cells co-transfected with BAP-MHC-Ia and cyt-BirA (control) and, where indicated, with US2 or US11 in the absence (2) or presence of MG132 (MG; 50 μM for 4 h) or Bortezomib(Bort.; 50 μM for 4 h).

    PLoS One 2011 6, e23712. Bortezomib (PS-341) purchased from Selleck.

     

    KKU-M213 was treated with BTZ as indicated. Total cell lysate ( a) and nuclear extract (b) were prepared. Actin and γ -tubulin were loading controls for total and nuclear proteins, respectively.

    2011 Mireia Vila Gasull University of Porto. Bortezomib (PS-341) purchased from Selleck.

  • Mireia Vila Gasull University of Porto. 2011;Mireia Vila Gasull . Bortezomib (PS-341) purchased from Selleck.

製品安全説明書

Proteasome阻害剤の選択性比較

生物活性

製品説明 Bortezomib (PS-341) is a potent 20S proteasome inhibitor with Ki of 0.6 nM. It exhibits favorable selectivity towards tumor cells over normal cells.
ターゲット
20S proteasome [1]
(Cell-free assay)
0.6 nM(Ki)
体外試験

Bortezomib, a boronic acid dipeptide, is a highly selective, reversible inhibitor of the 26S proteasome which primarily functions in the degradation of mis-folded proteins and is essential for the regulation of the cell cycle. Exposure to Bortezomib has been shown to stabilize p21, p27, and p53, as well as the proapoptotic Bid and Bax proteins, caveolin-1, and inhibitor κB-α, which prevents activation of nuclear factor κB-induced cell survival pathways. Bortezomib also promotes the activation of the proapoptotic c-Jun-NH2 terminal kinase, as well as the endoplasmic reticulum stress response. Alteration of the levels of these cellular proteins leads to inhibition of proliferation, migration, and promotion of apoptosis of cancer cells. [2] Bortezomib is shown to penetrate into cells and inhibit proteasome-mediated intracellular proteolysis of long-lived proteins with a concentration that inhibits 50% of the proteolysis of ∼0.1 μM. The average growth inhibition of 50% value for Bortezomib across the entire panel of 60 cancer cell lines derived from multiple human tumors from the US National Cancer Institute (NCI) is 7 nM. Treatment of PC-3 cells with Bortezomib (100 nM) for 8 h results in the accumulation of cells in G2-M, with a corresponding decrease in the number of cells in G1. Bortezomib kills PC-3 cells at 24 and 48 hr with IC50 of 100 and 20 nM, respectively. Bortezomib induces nuclear condensation at 16–24 hr after treatment. Bortezomib treatment leads to PARP cleavage in a time-dependent manner with concentrations as low as 100 nM being effective at 24 hr. [1]

細胞データ
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
MCF-7 MlK2R5l1d3SxeHnjJGF{e2G7 M1S4cFUxKM7:TR?= M{[wTVQ5KGh? MmDiSG1UVw>? M1fiO2tqdGy|IHPlcIx{KGK7IH3vdoUhfGijbjC5PUU> MmP0NVA1QTl4NEO=
OVCA 429 M4XNVWZ2dmO2aX;uJGF{e2G7 NG\KcWM{ODBibl2= M4r0UFQ5KGh? NWjSeIxoTE2VTx?= MkfOSIl{enWydIOgbY51[WO2IH31cJRq[2WubIXsZZIhfHWvb4Kgd5Bp\XKxaXTz NHSx[ncyODl7OUe2Oi=>
RPMI8226 NVKyd|FoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1vq[lExOCCwTR?= NX3SO4ZVPDhiaB?= MkDpSG1UVw>? NI\1fGRKSzVyPUOwJI5O NUHhTHhtOTF|ME[0PFk>
Dox40 MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFjQbI4yODBibl2= NGf6[os1QCCq MmrFSG1UVw>? MVnJR|UxRTRyIH7N MnzYNVE{ODZ2OEm=
MR20 NUjBO4VIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYexNFAhdk1? MX60PEBp MkLISG1UVw>? MWjJR|UxRTJyIH7N M4PsdlEyOzB4NEi5
LR5 M4fzPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{X2SFExOCCwTR?= NXTmTWVOPDhiaB?= NEjTUJNFVVOR MmLXTWM2OD1{MDDuUS=> NVy1bmlIOTF|ME[0PFk>
U266 MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEfFWoQyODBibl2= M3znUlQ5KGh? MorFSG1UVw>? NIHQe3VKSzVyPUOgcm0> MXixNVMxPjR6OR?=
IM-9 MonaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWX1NZVkOTByIH7N MUC0PEBp Mo\CSG1UVw>? NFjYN|JKSzVyPU[gcm0> M4HzZlEyOzB4NEi5
Hs Sultan NXX2fYlMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NI\kUnAyODBibl2= NHzENG81QCCq NF;3Z3ZFVVOR MWPJR|UxRTJyIH7N M4rESVEyOzB4NEi5
PAM-LY2 NVH1NI0{TnWwY4Tpc44hSXO|YYm= MlLmNVAxKG6P MmrFNVIhcA>? MVnEUXNQ MnK1TY5pcWKrdIOgUmYu|rqEIHHjeIl3[XSrb36= MljDNVE{PTB7MUO=
PAM 212 M370PGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXOxNFAhdk1? NWDwO2tbPzJiaB?= NVTHUnlKTE2VTx?= MXXJcohq[mm2czDj[YxtKH[rYXLpcIl1gQ>? NUS1[pFbOTF|NUC5NVM>
PAM-LY2 M3:wTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NG\3SIsyODBibl2= MWO3NkBp M173fGROW09? M1jjZ2lvcGmkaYTzJINmdGxidnnhZoltcXS7 M3TK[lEyOzVyOUGz
B4B8 MnG1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MW[xNFAhdk1? NUjRPZk3PzJiaB?= NFrJ[21FVVOR NH3leFBKdmirYnn0d{Bk\WyuII\pZYJqdGm2eR?= MWWxNVM2ODlzMx?=
B7E3 NGfZ[mpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXmxNFAhdk1? MknXO|IhcA>? Mn7OSG1UVw>? Mof5TY5pcWKrdIOgZ4VtdCC4aXHibYxqfHl? MUmxNVM2ODlzMx?=
UM-SCC-9 NHLoTVNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXGxNFAhdk1? MVi3NkBp Mo\uSG1UVw>? NUC2RYt4UW6qaXLpeJMh[2WubDD2bYFjcWyrdIm= Ml;qNVE{PTB7MUO=
UM-SCC-11B NYXMNJQ3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mo\VNVAxKG6P NXHi[YZIPzJiaB?= MkLVSG1UVw>? M17KUmlvcGmkaYTzJINmdGxidnnhZoltcXS7 M4nVc|EyOzVyOUGz
H460 NE\MOGtHfW6ldHnvckBCe3OjeR?= M{PIRlExKM7:TR?= MlXBNlQhcA>? NXnxXG43TE2VTx?= MXfJcoR2[2W|IFLjcE0zKHCqb4PwbI9zgWyjdHnvckBidmRiY3zlZZZi\2ViY3;ydoVt[XSnZDD3bZRpKEd{LV2gdIhie2ViYYLy[ZN1 M1LRZ|EzPDl{MUG3
U266 NHzYfHpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXTx[G85PTByIH7nM41t MljLOFghcA>? Mlu3SG1UVw>? MUDJcohq[mm2czDj[YxtKGe{b4f0bC=> MWexNlY{OTZzOR?=
ARH77 MkTqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1XvcVUxOCCwZz;tcC=> NXrxdIpRPDhiaB?= NFvodJNFVVOR NVfnXY5rUW6qaXLpeJMh[2WubDDndo94fGh? NYjaPWN{OTJ4M{G2NVk>
WAD-1 MorxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVPLXI5SPTByIH7nM41t NFXGZ2E1QCCq NIXzZlNFVVOR MUHJcohq[mm2czDj[YxtKGe{b4f0bC=> MkXnNVI3OzF4MUm=
U266/LR7 NYezdotkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEH3Zng2ODBibnevcYw> M4nXc|Q5KGh? NVm0RmEyTE2VTx?= NV[5dVFJUW6qaXLpeJMh[2WubDDndo94fGh? NHTvZnoyOjZ|MU[xPS=>
U266/dox4 MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{nqeVUxOCCwZz;tcC=> M{HoV|Q5KGh? MmHHSG1UVw>? Mkn1TY5pcWKrdIOgZ4VtdCCpcn;3eIg> NIPNTIMyOjZ|MU[xPS=>
RPMI8226/LR5 MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXK1NFAhdmdxbXy= M4fW[VQ5KGh? MXPEUXNQ NYK3NYU{UW6qaXLpeJMh[2WubDDndo94fGh? MUmxNlY{OTZzOR?=
H460 MnXGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MojONVAh|ryP NHrmeJg4OiCq MnXvSG1UVw>? NWLnNph[UUN3ME2xNFAhdk1? NIOxSXIyOjZ|MU[yNC=>
H358 Ml\4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4Hl[|ExKM7:TR?= MUS3NkBp NXXTfm1QTE2VTx?= NWjEdm9QUUN3ME23NEBvVQ>? MVixNlY{OTZ{MB?=
H322 MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1rtc|ExKM7:TR?= NGXnRpU4OiCq MUPEUXNQ Mm\VTWM2OD14MkCgcm0> MVWxNlY{OTZ{MB?=
H460 MkPGSpVv[3Srb36gRZN{[Xl? NUXQPVNQOTByIH7N MWmyOEBp NXzGWVd[TE2VTx?= MXnJcoR2[2W|IFeyMW0ueGijc3WgZZJz\XO2IHHu[EB1fWK3bHnuJIF{e2WvYnz5MYRqe2G|c3XtZox6 M4LDZlEzPjNzNkKw
LNCap-Pro5 NWTZVIZ1TnWwY4Tpc44hSXO|YYm= MVOxJO69VQ>? MYS0JIg> NVPyRpM1TE2VTx?= NYP4SVBbW3SjYnnsbZpmeyCyNUO= NWfYWI5EOTR4MUK1N|I>
T29 MYHBdI9xfG:|aYOgRZN{[Xl? MXq1NEBvVQ>? NGDPNnU1QCCqIB?= MV7EUXNQ MXvJcoR2[2W|IHPlcIwh[XCxcITvd4l{ MX6xOlc4QDF5OR?=
T29Kt1 M1[yVWFxd3C2b4Ppd{BCe3OjeR?= M4TpWFUxKG6P NVXXemJsPDhiaDC= NGPrdXZFVVOR MkfWTY5lfWOnczDj[YxtKGGyb4D0c5Nqew>? NWLTRnRyOTZ5N{ixO|k>
HCT116 M2j0SGFxd3C2b4Ppd{BCe3OjeR?= MoPMOVAhdk1? NGn6VnE1QCCqIB?= Mm\wSG1UVw>? M3\yTWlv\HWlZYOgZ4VtdCCjcH;weI9{cXN? MnzCNVY4PzhzN{m=
HKe-3 MX7BdI9xfG:|aYOgRZN{[Xl? NUjpe|JmPTBibl2= NV3qbpZ4PDhiaDC= MY\EUXNQ MkjLTY5lfWOnczDj[YxtKGGyb4D0c5Nqew>? MUmxOlc4QDF5OR?=
NB-1691 MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkS4NUDPxE1? NEfadHI4OiCq NUX2cmNtUW6qaXLpeJMh[2WubDDwdo9tcW[ncnH0bY9vKHSxIEWl M3rsXFE4Pjh7Nki0
CHLA-255 NVjxVph5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3HZdlEh|ryP NHy4XYs4OiCq MVPJcohq[mm2czDj[YxtKHC{b3zp[oVz[XSrb36geI8hOiV? MWixO|Y5QTZ6NB?=
SK-N-AS MnfnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4H1T|Eh|ryP MVq3NkBp MUXJcohq[mm2czDj[YxtKHC{b3zp[oVz[XSrb36geI8hOTBn MUGxO|Y5QTZ6NB?=
NB-1691 NGXzToRHfW6ldHnvckBCe3OjeR?= NX[0dnIxOTBibl2= MX6yOEBp MljzV4lodmmoaXPhcpRtgSC{ZXT1Z4V{KGOnbHzzJIlvKHSqZTDHNE9IOSCyaHHz[S=> MVOxO|Y5QTZ6NB?=
CHLA-255 M2\NXWZ2dmO2aX;uJGF{e2G7 M4\aZ|ExKG6P MlfQNlQhcA>? M3n2fm1w\GW|dHz5JJJm\HWlZYOgZ4VtdHNiaX6geIhmKEdyL1exJJBp[XOn M4rIVlE4Pjh7Nki0
RPMI 8226 MnHjSpVv[3Srb36gRZN{[Xl? MU[yNEBvVQ>? MmjpPEBp MXHTbYdvcW[rY3HueIx6KGWwaHHuZ4V{KE6ILd86RkBi[3Srdnn0fS=> MYWxPVQ{PjB3MB?=
MM.1S M3HRZmZ2dmO2aX;uJGF{e2G7 NVvXR2VTOjBibl2= MVG4JIg> M2SzZ3Nq\26rZnnjZY51dHliZX7oZY5k\XNiTl[t{tpDKGGldHn2bZR6 MnvhNVk1OzZyNUC=
U266 NVe4SVQxTnWwY4Tpc44hSXO|YYm= M1vXV|IxKG6P M4rBfVghcA>? NWPPRY9HW2mpbnnmbYNidnSueTDlcohidmOnczDOSk3PwkJiYXP0bZZqfHl? MlHrNVk1OzZyNUC=
OPM1 NV\K[5R5TnWwY4Tpc44hSXO|YYm= NYX1RnB3OjBibl2= NUnjc5BEQCCq MYPTbYdvcW[rY3HueIx6KGWwaHHuZ4V{KE6ILd86RkBi[3Srdnn0fS=> NYnBUlhxOTl2M{[wOVA>
INA6 NFXVc5lHfW6ldHnvckBCe3OjeR?= MWOyNEBvVQ>? M2DjUVghcA>? MUXTbYdvcW[rY3HueIx6KGWwaHHuZ4V{KE6ILd86RkBi[3Srdnn0fS=> MVyxPVQ{PjB3MB?=
OPM2 MoXHSpVv[3Srb36gRZN{[Xl? Mk\vNlAhdk1? M3HzUlghcA>? NGP2OpdUcWewaX\pZ4FvfGy7IHXubIFv[2W|IF7GMe67SiCjY4Tpeol1gQ>? NYOyWIZiOTl2M{[wOVA>
RPMI 8226 NYPD[GVYTnWwY4Tpc44hSXO|YYm= NWL6Um1UOjBibl2= MWW4JIg> NWfGNZNJUW6mdXPld{BFVkFic4nueIhme2m| M{HrZVE6PDN4MEWw
BaF/3 NVzFfJdRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkT0NVAxKG6P MWe0PEBp NVzSbGc5UUN3ME22MlIhdk1? M{\QTVIxOzB3Nkmy
BaF/3-p210 NFXDOnFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1zOTFExOCCwTR?= M1;3c|Q5KGh? Mk\ZTWM2OD12Lkegcm0> MnXFNlA{ODV4OUK=
TCC-S MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVKxNFAhdk1? NFLCT2o1QCCq NEHXeIxKSzVyPUKuPEBvVQ>? M2n3U|IxOzB3Nkmy
BaF/3 NEDnd2hHfW6ldHnvckBCe3OjeR?= MYW2JI5O M2XJZVQ5KGh? NVLENY4{UW6mdXPld{BiKGe{ZXH0JGcyKGOnbHytZ5lkdGViYYLy[ZN1 M4m2dVIxOzB3Nkmy
BaF/3-p210 MUnGeY5kfGmxbjDBd5NigQ>? MWS2JI5O Mn;SOFghcA>? MmTUTY5lfWOnczDhJJNtcWeqdDDHNUBk\WyuLXP5Z4xmKGG{cnXzeC=> MXqyNFMxPTZ7Mh?=
BaF/3-p210 NUPTU5JvTnWwY4Tpc44hSXO|YYm= NXr1R3VxPiCwTR?= M3j0SFI1KGh? MnLqVoVlfWOnczD0bIUheGixc4Doc5J6dGG2aX;uJIFv\CC2aHWgZYN1cX[rdImgc4YhWmJ? M2LlblIxOzB3Nkmy
Raji NWTKb4lRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NH;4eYYyKM7:TR?= NU[3NZBpOjRiaB?= MkHkVoVlfWOnczDj[YxtKH[rYXLpcIl1gcLi NHrr[44zOTF5MEm4PC=>
LCL-1 MmDFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlrsNUDPxE1? MkXpNlQhcA>? Mn7tVoVlfWOnczDj[YxtKH[rYXLpcIl1gcLi M{TaNVIyOTdyOUi4
LCL-2 M1PTSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWCxJO69VQ>? MlGxNlQhcA>? MWrS[YR2[2W|IHPlcIwhfmmjYnnsbZR6yqB? MmXVNlEyPzB7OEi=
BJAB NVvJS5NKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mn;ENUDPxE1? NVKyd5BKOjRiaB?= Ml\FVoVlfWOnczDj[YxtKH[rYXLpcIl1gcLi M1yw[|IyOTdyOUi4
SNT-13 M4TTcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mle3NUDPxE1? MlHXNlQhcA>? M{n3UHJm\HWlZYOgZ4VtdCC4aXHibYxqfHoEoB?= MV:yNVE4ODl6OB?=
SNT-16 M1;2Wmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MX6xJO69VQ>? NVfpdYJUOjRiaB?= NVrZVHhPWmWmdXPld{Bk\WyuII\pZYJqdGm2edMg NF73[FYzOTF5MEm4PC=>
Jurkat M4rOVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MV6xJO69VQ>? NF3OOlkzPCCq NWDMVlM1WmWmdXPld{Bk\WyuII\pZYJqdGm2edMg MmDxNlEyPzB7OEi=
KAI-3 NI\4[4NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHfwW|UyKM7:TR?= M{PQcFI1KGh? M13kPHJm\HWlZYOgZ4VtdCC4aXHibYxqfHoEoB?= M1OxelIyOTdyOUi4
SNK-6 NXTjcmpiT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlrnNUDPxE1? MoHvNlQhcA>? M2TFdHJm\HWlZYOgZ4VtdCC4aXHibYxqfHoEoB?= NEnHbYUzOTF5MEm4PC=>
KHYG-1 MnqwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIH2SoEyKM7:TR?= MUKyOEBp M3O2PHJm\HWlZYOgZ4VtdCC4aXHibYxqfHoEoB?= NXXVTZRxOjFzN{C5PFg>
SNT-16 MmXnRZBweHSxc3nzJGF{e2G7 NXnIXWp[OSEQvF2= NIP4cJA3KGh? M{nQUmlv\HWlZYOgZ4VtdCCjcH;weI9{cXN? MVuyNVE4ODl6OB?=
Jurkat NV75ZWlPSXCxcITvd4l{KEG|c3H5 M3LqR|Eh|ryP MnqxOkBp NFz6cmJKdmS3Y3XzJINmdGxiYYDvdJRwe2m| NXTnNGoyOjFzN{C5PFg>
KAI-3 M4rlTWFxd3C2b4Ppd{BCe3OjeR?= NYXvVphIOSEQvF2= MoDhOkBp NUDaOnlEUW6mdXPld{Bk\WyuIHHwc5B1d3Orcx?= NGfve3ozOTF5MEm4PC=>
KHYG-1 NIjBdm5CeG:ydH;zbZMhSXO|YYm= MoLXNUDPxE1? NYD1[ok5PiCq M2P6[2lv\HWlZYOgZ4VtdCCjcH;weI9{cXN? MXWyNVE4ODl6OB?=
SNT-13 MYrBcpRqfmm{YXygRZN{[Xl? MYWxJO69VQ>? MUeyOEBp M3nNPWlv\HWlZYOgcJl1cWNiaX7m[YN1cW:wIH;mJGVDXg>? MoLoNlEyPzB7OEi=
SNT-16 MWXBcpRqfmm{YXygRZN{[Xl? MkTZNUDPxE1? M3XKSFI1KGh? MV\JcoR2[2W|IHz5eIlkKGmwZnXjeIlwdiCxZjDFRnY> MmfPNlEyPzB7OEi=
KAI-3 NHra[YVCdnSrdnnyZYwhSXO|YYm= NIPkWHYyKM7:TR?= M{fZclI1KGh? MoXGTY5lfWOnczDsfZRq[yCrbn\lZ5Rqd25ib3[gSWJX NYD6XmtbOjFzN{C5PFg>
SNK-6 M2LWPGFvfGm4aYLhcEBCe3OjeR?= MXqxJO69VQ>? MlPXNlQhcA>? M4XzV2lv\HWlZYOgcJl1cWNiaX7m[YN1cW:wIH;mJGVDXg>? NUT1WWxVOjFzN{C5PFg>
RAW 264.7 Ml;5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NI\nTpMyODBibl2= MX:0PEBp NWS1fmc6WmWmdXPld{Bk\WyuII\pZYJqdGm2edMg MoLTNlI1OjdzNUS=
A375 NIK1S4lCeG:ydH;zbZMhSXO|YYm= M4LRUVExKG6P NEToOGQzPCCq NF7Tc4lKdmS3Y3XzJINmdGxiYYDvdJRwe2m| MkXoNlMxPzlyOEO=
BLM NYjVXYpXSXCxcITvd4l{KEG|c3H5 NG[4O|MyOCCwTR?= M2jveFI1KGh? MkjCTY5lfWOnczDj[YxtKGGyb4D0c5Nqew>? M4T6PFI{ODd7MEiz
A375 NGjXUXdCfXSxcHjh[5khSXO|YYm= Mn3mNVAhdk1? NYrF[IdGOTJiaB?= MYnJcoR2[2W|IH\vdo1ifGmxbjDv[kBifXSxcHjh[49{d22ncx?= NXLBRoNyOjNyN{mwPFM>
BLM M{T3T2F2fG:yaHHnfUBCe3OjeR?= M1PiWlExKG6P MWWxNkBp M3;DdWlv\HWlZYOg[o9zdWG2aX;uJI9nKGG3dH;wbIFod3OxbXXz M{Lhe|I{ODd7MEiz
H1299 MnO3RZBweHSxc3nzJGF{e2G7 NXK5OWpiQDBibl2= MWOyOEBp MYjEUXNQ NEHFZmJU\W6|aYTpfoV{KE6VQ1zDJINmdGy|IITvJG1USy2mZYLpeoVlKGmFOT3pcoR2[2WmIHHwc5B1d3Orcx?= NUfScoQ4OjV|MkO2PVM>
Hut-78 MlvpSpVv[3Srb36gRZN{[Xl? NVO3NJc1OTByIH7N NFz1dlgzPCCq MnLzSG1UVw>? M2C2[GRwf26{ZXf1cIF1\XNiVFfGMe6zOSCjbnSgTWwuOTBiZYjwdoV{e2mxbh?= MUCyOVY5OTN|NR?=
H9 Mk\jSpVv[3Srb36gRZN{[Xl? NFPUZnMyODBibl2= MUCyOEBp M1;KRWROW09? NVu1Tm9KTG:5boLl[5Vt[XSnczDUS2Yu|rJzIHHu[EBKVC1zMTDlfJBz\XO|aX;u M3zWdlI2PjhzM{O1
HH NUT1flhyTnWwY4Tpc44hSXO|YYm= NF7reoYyODBibl2= M3HiPVI1KGh? Mlm2SG1UVw>? NFXUOo1ld3ewcnXneYxifGW|IGTHSk3PujFiYX7kJGlNNTF{IHX4dJJme3Orb36= MkCyNlU3QDF|M{W=
Hut-78 M2jSem1q\3KjdHnvckBCe3OjeR?= MU[xNFAhdk1? M3XwelI1KGh? NEjUb2dFVVOR MXHS[YR2[2W|IHPlcIwhdWmpcnH0bY9vKGK7IEiw5qCUQTBn M4jpclI2PjhzM{O1
HH NX7YemF2VWmpcnH0bY9vKEG|c3H5 Moe5NVAxKG6P NFLWSmUzPCCq NUCxfVc6TE2VTx?= NXjuVlVDWmWmdXPld{Bk\WyuIH3p[5JifGmxbjDifUA5OOLCk{mxKS=> M3fXWVI2PjhzM{O1
U937 NX23[XMxTnWwY4Tpc44hSXO|YYm= M{m5cVExOCCwTR?= M{LIV|YhcA>? M2W3Rmlv\HWlZYOgTWwuQCCneIDy[ZN{cW:wIHnuJGxRWy2|dHnteYxifGWmIGW5N|chdWGlcn;wbIFo\XN? MnziNlU4QTF2N{e=
human PBMC NWrnZmtlTnWwY4Tpc44hSXO|YYm= MWKxNFAhdk1? NFTuTmIzPCCq M4PKPWlv\HWlZYOgTWwuQCC{ZXzlZZNm MWOyOVc6OTR5Nx?=
ES6 NF7TTIdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MV;JR|UxRTBwMECyNUBvVQ>? Ml3oV2FPT0WU
SK-UT-1 NXv3Xnl{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3XsUGlEPTB;MD6xOlMhdk1? NY[0[2hDW0GQR1XS
SH-4 M4CzeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVzJR|UxRTBwMUezJI5O NU\Zb3Y6W0GQR1XS
TE-9 MmS2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M16xZWlEPTB;MD6xPFIhdk1? MnLVV2FPT0WU
A253 MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3\rSGlEPTB;MD6yNFghdk1? MkKzV2FPT0WU
no-10 NHXTXoFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NF24[4dKSzVyPUCuNlEhdk1? NFyzdoVUSU6JRWK=
MMAC-SF MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIfWSY1KSzVyPUCuNlE3KG6P MnPiV2FPT0WU
A101D MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NG\yfoZKSzVyPUCuNlI2KG6P M{XHXnNCVkeHUh?=
NTERA-S-cl-D1 MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4XtUGlEPTB;MD6yOFMhdk1? NWex[5duW0GQR1XS
8-MG-BA NWS2ZmtGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Ml3XTWM2OD1yLkK1JI5O NVHKW45zW0GQR1XS
KNS-42 M1nCd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3ewc2lEPTB;MD6yOVghdk1? MY\TRW5ITVJ?
LXF-289 M{fSNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mk\GTWM2OD1yLkK2PUBvVQ>? MnXDV2FPT0WU
OVCAR-4 MlPSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NH7IXZJKSzVyPUCuNlg6KG6P MYPTRW5ITVJ?
LOUCY NYfzRYFqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1K1fGlEPTB;MD6yPVMhdk1? M1jJ[XNCVkeHUh?=
BB65-RCC MlnvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYDJR|UxRTBwM{C0JI5O MWnTRW5ITVJ?
D-542MG M3TXNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2HMeGlEPTB;MD6zNlkhdk1? MV\TRW5ITVJ?
ONS-76 NEjpbVBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXXJR|UxRTBwM{Ogcm0> NHvn[2ZUSU6JRWK=
BB30-HNC Ml;aS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFLhR5VKSzVyPUCuN|M2KG6P NWriS5d3W0GQR1XS
KS-1 NHTrZ5ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVTJR|UxRTBwM{Sgcm0> MVXTRW5ITVJ?
A388 M1Gy[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlHXTWM2OD1yLkO1OkBvVQ>? MmK4V2FPT0WU
ES8 NHHFWZFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmXVTWM2OD1yLkSgcm0> MUfTRW5ITVJ?
MZ2-MEL NEXEVWVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUK2fZp{UUN3ME2wMlQxPyCwTR?= NFLyblJUSU6JRWK=
HCC2998 NU\DXFhUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWLmc5lNUUN3ME2wMlQyOiCwTR?= M4DLcHNCVkeHUh?=
D-247MG NF72VpBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NY\KcZNoUUN3ME2wMlQyOyCwTR?= MmSzV2FPT0WU
ACN M4jod2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYfBSotiUUN3ME2wMlQyPyCwTR?= M{nHUnNCVkeHUh?=
LB2518-MEL MkHqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGPhemxKSzVyPUCuOFI2KG6P MnvrV2FPT0WU
ES1 NWniXphtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NG\qNJlKSzVyPUCuOFMhdk1? Moi1V2FPT0WU
HCE-T NYPifmhGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXrVTmF7UUN3ME2wMlQ{QSCwTR?= MojVV2FPT0WU
OS-RC-2 NHO4OpRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NH71S2NKSzVyPUCuOFQhdk1? NYrFTnFkW0GQR1XS
MFH-ino NGHrWIFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHr2TI1KSzVyPUCuOFQ{KG6P Mo\CV2FPT0WU
OCUB-M NF7mb2RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYX3ZnMxUUN3ME2wMlQ1PyCwTR?= M372UHNCVkeHUh?=
CP66-MEL NV;KbnFqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIe2XZdKSzVyPUCuOFc{KG6P NYDofpFtW0GQR1XS
LB771-HNC NUn6RYJRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NV\4RY5JUUN3ME2wMlQ4PCCwTR?= M2HCenNCVkeHUh?=
DSH1 M{HlUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mo\DTWM2OD1yLkS4JI5O M2XwfXNCVkeHUh?=
HUTU-80 M1;2Umdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUL4Z2k6UUN3ME2wMlU{OyCwTR?= MlfBV2FPT0WU
CESS MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3ThXGlEPTB;MD61N|ghdk1? MkfPV2FPT0WU
NCI-H747 NITUOo5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFPkbmFKSzVyPUCuOVM6KG6P M3HMN3NCVkeHUh?=
HT-144 MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYHJR|UxRTBwNUe2JI5O NXnONnVRW0GQR1XS
COLO-829 NWm1[mF7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYW4RoZ7UUN3ME2wMlYyPCCwTR?= M{\FXHNCVkeHUh?=
A4-Fuk MoHuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mn3rTWM2OD1yLk[yN{BvVQ>? NEXDWoZUSU6JRWK=
GI-ME-N NXLIdnppT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWTC[Y1mUUN3ME2wMlY{PCCwTR?= MlXEV2FPT0WU
LB831-BLC MnTZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{f1cWlEPTB;MD62OFEhdk1? M1fmNHNCVkeHUh?=
HOP-62 Mo\RS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NG\Rd4ZKSzVyPUCuOlQ4KG6P MVPTRW5ITVJ?
BB49-HNC M4T3eGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MojoTWM2OD1yLk[1NkBvVQ>? MmPoV2FPT0WU
D-336MG MkX1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWDJR|UxRTBwNkW3JI5O MXHTRW5ITVJ?
TK10 MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlnUTWM2OD1yLk[3PUBvVQ>? MYDTRW5ITVJ?
Ramos-2G6-4C10 NE\VdIZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGP2cpFKSzVyPUCuOlk{KG6P NUjH[IFXW0GQR1XS
LB373-MEL-D NEL3cHlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWWwO45CUUN3ME2wMlchdk1? MmPjV2FPT0WU
SF126 M{jOdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUTJR|UxRTBwN{CxJI5O NF3t[lJUSU6JRWK=
UACC-257 M3LvcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mlz2TWM2OD1yLkexJI5O MXjTRW5ITVJ?
KINGS-1 M3TSdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MV;JR|UxRTBwN{KyJI5O MmPFV2FPT0WU
LS-513 MlX2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYD2[nREUUN3ME2wMlc{QSCwTR?= M4rXNXNCVkeHUh?=
GI-1 MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFz6RZBKSzVyPUCuO|Y1KG6P NXTHU|BsW0GQR1XS
ES7 MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVrrN41IUUN3ME2wMlc3PiCwTR?= M1rEV3NCVkeHUh?=
LB2241-RCC NXu0PFdtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWe3SodRUUN3ME2wMlgxPCCwTR?= Mo\2V2FPT0WU
D-263MG M4\kUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmPTTWM2OD1yLkiwO{BvVQ>? NHvROZlUSU6JRWK=
SW684 MnPQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MW\JR|UxRTBwOEKxJI5O MXjTRW5ITVJ?
ML-2 MoPQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYXSfGdEUUN3ME2wMlgzOSCwTR?= MXXTRW5ITVJ?
SK-LMS-1 MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHHPbnpKSzVyPUCuPFU1KG6P MWPTRW5ITVJ?
TE-5 NVSyenhFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NE\mS45KSzVyPUCuPFY2KG6P NHHGeXdUSU6JRWK=
QIMR-WIL NHTnVpVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoPqTWM2OD1yLki4PUBvVQ>? M1ixXHNCVkeHUh?=
NCI-H1355 M3rqU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MV3JR|UxRTBwOEm1JI5O MX\TRW5ITVJ?
SNB75 NVGxVWVPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NY\3XXFsUUN3ME2wMlkyOiCwTR?= NV7BTIROW0GQR1XS
RXF393 M3yzU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mlu1TWM2OD1yLkmxOEBvVQ>? M124bHNCVkeHUh?=
IST-MEL1 MoDNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVTP[ZExUUN3ME2wMlkyPyCwTR?= NYj5dmhzW0GQR1XS
SF268 NXTEXHF5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWXNTY1SUUN3ME2wMlkzOyCwTR?= M{KyW3NCVkeHUh?=
KALS-1 M2LxbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NI\nSY5KSzVyPUCuPVI2KG6P MWTTRW5ITVJ?
HC-1 Mk\lS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnvnTWM2OD1yLkm3OUBvVQ>? NYixSZU2W0GQR1XS
SW872 NVPvNXJmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnnNTWM2OD1yLkm5OkBvVQ>? NWHldWZyW0GQR1XS
PSN1 NX3IWVhPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVXJR|UxRTFwMEGgcm0> MVjTRW5ITVJ?
TE-1 Mn3CS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mm\OTWM2OD1zLkCzJI5O NUDCdlJnW0GQR1XS
TE-10 MkHlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NF3zcnVKSzVyPUGuNFMhdk1? M3LuV3NCVkeHUh?=
RKO NHPzUnlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXexUmkxUUN3ME2xMlA3KG6P NFrVVGpUSU6JRWK=
LC-2-ad M1jpcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmHLTWM2OD1zLkC4JI5O NWHwOlJHW0GQR1XS
SK-MM-2 Mn\3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHnieWxKSzVyPUGuNFkhdk1? M{fydXNCVkeHUh?=
VA-ES-BJ NGXsVHVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4HDSmlEPTB;MT6wPUBvVQ>? M{i3dHNCVkeHUh?=
MZ7-mel M{XZVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MX3JR|UxRTFwMEmgcm0> NYnUV3VtW0GQR1XS
D-392MG MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlrHTWM2OD1zLkGgcm0> NFLqbVZUSU6JRWK=
CCRF-CEM MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkDiTWM2OD1zLkGzJI5O NUXhOXhUW0GQR1XS
EM-2 MnTTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVG5UoFPUUN3ME2xMlE3KG6P MX3TRW5ITVJ?
HAL-01 NEXGOVdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mnq1TWM2OD1zLkG4JI5O MnrNV2FPT0WU
TE-8 NU\k[G1NT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4jncmlEPTB;MT6xPUBvVQ>? NUDK[2JHW0GQR1XS
NCI-H1882 NWjJdJQzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2raZ2lEPTB;MT6yJI5O Mk[wV2FPT0WU
Daudi NV7iPFIxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGGzXWpKSzVyPUGuNlIhdk1? MVnTRW5ITVJ?
BL-41 NGe1S4pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUXJR|UxRTFwMkWgcm0> MWnTRW5ITVJ?
SR M3;Wb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MX;JR|UxRTFwMkWgcm0> NEOyV4FUSU6JRWK=
KM12 NWHP[GZ4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGPRNYFKSzVyPUGuNlchdk1? M{\MenNCVkeHUh?=
K5 NHX3dXhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGXaXWZKSzVyPUGuNlghdk1? NGfrOmRUSU6JRWK=
A3-KAW NVjXVWR7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHzyd4hKSzVyPUGuNlghdk1? MWLTRW5ITVJ?
CMK NYm1[3lJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2DEeGlEPTB;MT6yPUBvVQ>? M3jaZXNCVkeHUh?=
Calu-6 NXj1UYx[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmO4TWM2OD1zLkK5JI5O NYDQXG5bW0GQR1XS
IST-SL2 NWnJNZZ3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NH3Xcm1KSzVyPUGuN|Ehdk1? MlX6V2FPT0WU
OPM-2 M4K3Rmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmeyTWM2OD1zLkOzJI5O NUTqflA2W0GQR1XS
DU-4475 NIDJTXFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVnYdoRYUUN3ME2xMlM3KG6P NYG0bolGW0GQR1XS
ECC12 NF32d2xIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWHJR|UxRTFwM{egcm0> Mom0V2FPT0WU
L-540 NVHFfmxRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4DBW2lEPTB;MT6zO{BvVQ>? MXPTRW5ITVJ?
CAS-1 NVW3Wpc{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NF:0flBKSzVyPUGuN|chdk1? NFjOXpJUSU6JRWK=
PF-382 MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEfrTHhKSzVyPUGuOFchdk1? MkSwV2FPT0WU
LS-411N NXzTfXZvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlO0TWM2OD1zLkWzJI5O NInKR2VUSU6JRWK=
NCI-H69 M2TmO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYXJR|UxRTFwNUSgcm0> NVLm[ZBVW0GQR1XS
NB12 Mk\SS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVjJR|UxRTFwNU[gcm0> MmrBV2FPT0WU
HEL MlLyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXvrbm1rUUN3ME2xMlYyKG6P NULXe206W0GQR1XS
GCIY NG\GeFZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3L3VWlEPTB;MT62NkBvVQ>? NXXoNYt2W0GQR1XS
EHEB M3PxZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHjSfmZKSzVyPUGuOlchdk1? NFfkcnpUSU6JRWK=
TGBC1TKB NYq0WnBuT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3XhRWlEPTB;MT63NUBvVQ>? MYPTRW5ITVJ?
KURAMOCHI MkW4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NF7hO4FKSzVyPUGuO|Ihdk1? MXrTRW5ITVJ?
U-266 MlnrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVXJR|UxRTFwN{[gcm0> MYfTRW5ITVJ?
LC4-1 M2D5SGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIXsPFVKSzVyPUGuO|khdk1? M3XtdHNCVkeHUh?=
NCI-H2126 NFLvNmlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVTScGp4UUN3ME2xMlghdk1? M3jkRnNCVkeHUh?=
NCI-H1092 M1L5OGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3vn[mlEPTB;MT64JI5O NH;DNmVUSU6JRWK=
GB-1 Mlr0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnTLTWM2OD1zLkixJI5O NIXFZo5USU6JRWK=
MV-4-11 MkTnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoLITWM2OD1zLkiyJI5O NX\JS3JEW0GQR1XS
Becker MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Ml\hTWM2OD1zLkizJI5O NIP6UVVUSU6JRWK=
MPP-89 MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYLJR|UxRTFwOEmgcm0> M{i3XXNCVkeHUh?=
BE-13 Ml7JS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHnyRnJKSzVyPUGuPVMhdk1? NYjUfllsW0GQR1XS
697 NXm3eI0{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUXJR|UxRTFwOUmgcm0> NILSenFUSU6JRWK=
NKM-1 NFPReXRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2HCSGlEPTB;MjDuUS=> NEnQNpBUSU6JRWK=
NB13 M3ezOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFL3SYRKSzVyPUKgcm0> NFrKWmZUSU6JRWK=
LS-123 MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mn\mTWM2OD1{LkCyJI5O MoTIV2FPT0WU
NB17 M1TSRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MV\JR|UxRTJwMESgcm0> Mmm3V2FPT0WU
LAN-6 M{HiXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXHJR|UxRTJwMEWgcm0> NFPYUm5USU6JRWK=
EW-24 M{\oOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHHtTHFKSzVyPUKuNFghdk1? MXvTRW5ITVJ?
NOS-1 Ml7NS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4niemlEPTB;Mj6xNUBvVQ>? MWXTRW5ITVJ?
BL-70 MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYrGZlNNUUN3ME2yMlEzKG6P MnSwV2FPT0WU
GT3TKB NHnUR3RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MV\JR|UxRTJwMUKgcm0> MlzZV2FPT0WU
HH M1;4b2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2HnT2lEPTB;Mj6xN{BvVQ>? M{jSTnNCVkeHUh?=
KE-37 NFPTSGlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVLJR|UxRTJwMUOgcm0> MVPTRW5ITVJ?
MOLT-4 NFrpeIRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2Lr[GlEPTB;Mj6xN{BvVQ>? M2j6UnNCVkeHUh?=
EKVX NIfBPVJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXvJR|UxRTJwMUSgcm0> MUjTRW5ITVJ?
KGN MmDzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NF;Bc4lKSzVyPUKuNVUhdk1? NUDxXHlVW0GQR1XS
ES4 MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4PwWmlEPTB;Mj6xOkBvVQ>? MVLTRW5ITVJ?
SJSA-1 MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnvmTWM2OD1{LkKxJI5O NVru[olKW0GQR1XS
KMOE-2 MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mk\6TWM2OD1{LkKzJI5O NEjn[|lUSU6JRWK=
NB5 NFPiXYpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NULpcJFXUUN3ME2yMlI4KG6P NHK4dZpUSU6JRWK=
BC-1 M1rwfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHHtVGhKSzVyPUKuN|Ehdk1? MoD0V2FPT0WU
NB10 NEfjV3JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUnJR|UxRTJwM{Kgcm0> MkXuV2FPT0WU
RPMI-8226 NHraT49Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2j1VmlEPTB;Mj6zOUBvVQ>? M4nifHNCVkeHUh?=
SCC-3 NWnLVYdGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlvkTWM2OD1{LkO3JI5O M362SHNCVkeHUh?=
ARH-77 MmT3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlzyTWM2OD1{LkO4JI5O NV;lUHJNW0GQR1XS
NCI-H748 NYLWeXA1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIPkNmlKSzVyPUKuN|khdk1? MlnLV2FPT0WU
KU812 NEGySmNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3K3XmlEPTB;Mj60NkBvVQ>? MmfqV2FPT0WU
NCI-H64 MkC0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MljOTWM2OD1{LkS0JI5O NHHjc2tUSU6JRWK=
NB69 M4DGVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnfZTWM2OD1{LkS2JI5O M{mwWXNCVkeHUh?=
KNS-81-FD NIfHZ5FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2fsTGlEPTB;Mj60PEBvVQ>? NILTTmFUSU6JRWK=
LB1047-RCC NIflVFNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NETCVYhKSzVyPUKuOVchdk1? NUHlUlN7W0GQR1XS
EB-3 M1zEbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mn3wTWM2OD1{Lk[2JI5O MVjTRW5ITVJ?
Mo-T NF;uWZFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUPKPFhGUUN3ME2yMlc1KG6P NEHCc2lUSU6JRWK=
EW-16 M2PCb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4fOVWlEPTB;Mj63OUBvVQ>? M{T4WXNCVkeHUh?=
CTV-1 M1j3SGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXTJR|UxRTJwODDuUS=> MVfTRW5ITVJ?
ETK-1 M2HnV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGfIcVRKSzVyPUKuPFQhdk1? NIeydG1USU6JRWK=
C2BBe1 NGK5[4VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXLkdnJvUUN3ME2yMlg6KG6P MVTTRW5ITVJ?
MOLT-16 MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYDJR|UxRTJwOEmgcm0> MVPTRW5ITVJ?
SW954 MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1PvdmlEPTB;Mj65JI5O NYH2NJdVW0GQR1XS
HT NYLjXJlCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXLJR|UxRTNwMEKgcm0> M4DlWHNCVkeHUh?=
KARPAS-299 MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVfKSFhmUUN3ME2zMlA3KG6P NFHySZBUSU6JRWK=
MONO-MAC-6 MlOwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFLqWo5KSzVyPUOuNUBvVQ>? NFHOVHZUSU6JRWK=
CGTH-W-1 NGn4THpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3LkZWlEPTB;Mz6xJI5O NE\YTG9USU6JRWK=
SK-PN-DW M3\i[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NF;QZVRKSzVyPUOuNVQhdk1? NWT5ZWllW0GQR1XS
CW-2 MnL5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MV3JR|UxRTNwMkGgcm0> NHHQSFVUSU6JRWK=
SK-N-DZ NYLhXVJZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4fKOmlEPTB;Mz6yOkBvVQ>? NH3hV2lUSU6JRWK=
NEC8 MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYD4SlV6UUN3ME2zMlM2KG6P NXHIPVgxW0GQR1XS
LB996-RCC MmDHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3rPO2lEPTB;Mz60JI5O NEH3VWZUSU6JRWK=
DB NWO0R4lIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2\ZRWlEPTB;Mz60NUBvVQ>? MX;TRW5ITVJ?
TE-15 MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGTFbXNKSzVyPUOuOFMhdk1? M{T2[HNCVkeHUh?=
COR-L88 M2q5[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWKwPJViUUN3ME2zMlQ4KG6P NHm3O3BUSU6JRWK=
LAMA-84 MnrvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3PkdmlEPTB;Mz60PUBvVQ>? NUT1S|NwW0GQR1XS
MEG-01 M4e4O2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MofkTWM2OD1|LkS5JI5O NX22OokxW0GQR1XS
LOXIMVI M1jrZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYrhb2FyUUN3ME2zMlUhdk1? NFqzbVBUSU6JRWK=
RPMI-8402 M3LPcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlLaTWM2OD1|LkWgcm0> NGrlVINUSU6JRWK=
KARPAS-45 NYT4VYZST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYjMUlY3UUN3ME2zMlU1KG6P MkLyV2FPT0WU
HCC1187 NI\UW4tIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkniTWM2OD1|LkW0JI5O NHLUVY1USU6JRWK=
MZ1-PC NUjnOJRGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYnJR|UxRTNwNUSgcm0> MVLTRW5ITVJ?
no-11 NXqxRoRFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYLNN5lbUUN3ME2zMlU2KG6P NX;hXZJpW0GQR1XS
EVSA-T M2j1Umdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUTYS|cxUUN3ME2zMlYhdk1? MmLhV2FPT0WU
DJM-1 M2LCcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mm[xTWM2OD1|Lk[zJI5O Ml\4V2FPT0WU
COLO-684 M4\PR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFn1W4JKSzVyPUOuOlYhdk1? NXK0Z|BJW0GQR1XS
NMC-G1 MnLrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1fET2lEPTB;Mz62PEBvVQ>? NUfpZpJTW0GQR1XS
LC-1F MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnzUTWM2OD1|Lke0JI5O MojOV2FPT0WU
RL95-2 NH\JPJFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXWwVW46UUN3ME2zMlc6KG6P MnrHV2FPT0WU
COLO-320-HSR MlrjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV\Gfo9YUUN3ME2zMlkzKG6P NXn3[mFSW0GQR1XS
RCC10RGB NVjCZpJ7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVHQZpJTUUN3ME2zMlk{KG6P NXP1XFhLW0GQR1XS
HD-MY-Z MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4myUWlEPTB;Mz65N{BvVQ>? MUnTRW5ITVJ?
NCI-H2141 NFvB[JRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{LlfGlEPTB;ND6wOUBvVQ>? NYX4Z4FXW0GQR1XS
K-562 Mlu0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NInLT4xKSzVyPUSuNVIhdk1? MmnLV2FPT0WU
NCI-H1648 NGj3cphIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVfkO2tmUUN3ME20MlE{KG6P NGfGSXpUSU6JRWK=
OMC-1 MnrBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnzmTWM2OD12LkG4JI5O NVvMSXo2W0GQR1XS
LB647-SCLC MlLtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYXJR|UxRTRwMkKgcm0> MUTTRW5ITVJ?
TE-12 MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHvVOJJKSzVyPUSuNlUhdk1? NGLDN|FUSU6JRWK=
NOMO-1 NIexXVNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVfJR|UxRTRwM{Ogcm0> MmjRV2FPT0WU
Raji NXqxb41WT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnnwTWM2OD12LkS2JI5O MoXzV2FPT0WU
NALM-6 M2PGdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NX7ReodzUUN3ME20MlQ6KG6P NUj5OWx3W0GQR1XS
HL-60 MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoHXTWM2OD12Lk[3JI5O M1XOWnNCVkeHUh?=
IST-SL1 NYLodpd{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFL1OHRKSzVyPUSuOlghdk1? MoX1V2FPT0WU
MHH-PREB-1 MmfXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWexfopzUUN3ME20Mlg3KG6P NULBb|dFW0GQR1XS
MHH-NB-11 NXfISG12T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVvj[2FsUUN3ME20MlkyKG6P NWLHPFZyW0GQR1XS
JiyoyeP-2003 M1KwcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXv0OFBFUUN3ME21JI5O MmKxV2FPT0WU
SBC-1 MmDYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWfJR|UxRTVwMEGgcm0> MoTlV2FPT0WU
CHP-126 MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mmf4TWM2OD13LkC2JI5O NVnpOGxGW0GQR1XS
LU-139 NIiweItIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXrJR|UxRTVwMUOgcm0> MWjTRW5ITVJ?
NCI-SNU-5 Ml\SS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVvJR|UxRTVwMUegcm0> NGHzUo9USU6JRWK=
SW962 MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NE\sXpFKSzVyPUWuNlEhdk1? NF3y[YVUSU6JRWK=
EW-1 NI\3SmhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NInEZZlKSzVyPUWuN|Ehdk1? NF;qZYNUSU6JRWK=
NCI-H1417 NYizTGpuT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NX25V4xxUUN3ME21MlUyKG6P MknUV2FPT0WU
LU-65 MnuxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mm\RTWM2OD13Lki0JI5O NID4V5RUSU6JRWK=
D-502MG MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFfzXHhKSzVyPU[uN|chdk1? MULTRW5ITVJ?
BC-3 NF[4e2xIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUPJR|UxRTZwNkGgcm0> MonOV2FPT0WU
GDM-1 NGX4fpFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUXYOIN3UUN3ME22Mlc4KG6P M{P1SHNCVkeHUh?=
NCI-H2196 NUi0eXZyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlPCTWM2OD14Lkigcm0> NFnLfXpUSU6JRWK=
NB1 M{fVO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NF7x[3NKSzVyPU[uPFghdk1? NUCzdnZ7W0GQR1XS
NCI-H345 NFLpXIxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MonrTWM2OD15LkKgcm0> M3LhfXNCVkeHUh?=
SU-DHL-1 M2L6N2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYLoc2xPUUN3ME23MlI1KG6P MX\TRW5ITVJ?
JVM-2 NHS4PFBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mmq2TWM2OD15LkK4JI5O MV;TRW5ITVJ?
LU-134-A NX;oToVYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmXRTWM2OD15LkO5JI5O NIjVO29USU6JRWK=
NCI-H1694 M1fjb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4HBemlEPTB;Nz61PEBvVQ>? MknoV2FPT0WU
NCI-SNU-16 MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFPO[4pKSzVyPUeuOlUhdk1? M2Dab3NCVkeHUh?=
L-363 MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFLtSIVKSzVyPUeuO{BvVQ>? MYnTRW5ITVJ?
KG-1 M1;jfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYXT[ItpUUN3ME23Mlk1KG6P NE[4S4dUSU6JRWK=
MN-60 MofqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUXJR|UxRThwMUSgcm0> MUPTRW5ITVJ?
NB6 MmPiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mm\yTWM2OD16LkS4JI5O Mo\XV2FPT0WU
MLMA NVHlWHhtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUXZUm9mUUN3ME24Mlg2KG6P NV7vdJloW0GQR1XS
ATN-1 NWDnTXo4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIDISFlKSzVyPUiuPFkhdk1? MYTTRW5ITVJ?
SK-NEP-1 NInGbWJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4[xc2lEPTB;OT6wNUBvVQ>? NVS3d3FwW0GQR1XS
DMS-114 MkXWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NECye4VKSzVyPUmuOlIhdk1? NUj3bpZIW0GQR1XS
CTB-1 Ml3QS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MU\JR|UxRTlwNkegcm0> NXfHeHJGW0GQR1XS
NCI-H2081 MmfUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXzNRo1LUUN3ME2xNE4xQSCwTR?= NWO4RXdbW0GQR1XS
ES5 MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1Hne2lEPTB;MUCuN|ghdk1? MWTTRW5ITVJ?
HCC1599 NYWweWdkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmH6TWM2OD1zMT65NUBvVQ>? MWXTRW5ITVJ?
NCI-H23 M3PERmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnjpTWM2OD1zMj6xNkBvVQ>? MV\TRW5ITVJ?
NCI-H1581 MlXhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXTJR|UxRTF{LkK4JI5O MlrUV2FPT0WU
JVM-3 NV7rOpk{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M17KfWlEPTB;MUKuPVkhdk1? MmD3V2FPT0WU
NCI-SNU-1 Mn3CS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnjwTWM2OD1zMz6xPUBvVQ>? M2\lbHNCVkeHUh?=
NB7 M4nVXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUfWSmZYUUN3ME2xOU46OiCwTR?= NYPyO2tLW0GQR1XS
JAR MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWLJR|UxRTF4LkGzJI5O MnrzV2FPT0WU
TGW M3L2R2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVnLSGF2UUN3ME2xOk41QCCwTR?= M{\SXHNCVkeHUh?=
U-87-MG MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MX;JR|UxRTF4Lke2JI5O NH;GcWFUSU6JRWK=
NCI-H1436 M1XMcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWDJR|UxRTF5LkCxJI5O NHXnTYNUSU6JRWK=
GOTO NYn2c2hzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4\GRWlEPTB;MUeuNFYhdk1? M4ju[3NCVkeHUh?=
COLO-800 NYnnZWxjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGnJbXhKSzVyPUG3MlY1KG6P NWHCb5Z[W0GQR1XS
MFM-223 MnLOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFPZWVZKSzVyPUG3MlkyKG6P Moe5V2FPT0WU
EW-18 NVHHV|R3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVvJR|UxRTF5Lkm2JI5O MmrGV2FPT0WU
NB14 MkjVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M33WSGlEPTB;MUeuPVghdk1? MVTTRW5ITVJ?
EB2 MlvtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWfJR|UxRTF6LkC4JI5O M1np[3NCVkeHUh?=
EoL-1- Mme5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFLiT|ZKSzVyPUG4MlMyKG6P NV;iUZRMW0GQR1XS
NCCIT M1zt[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4HyTmlEPTB;MUiuN|Yhdk1? M1mzdXNCVkeHUh?=
DG-75 NGTONVlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVrJR|UxRTF6Lk[xJI5O M1r6VHNCVkeHUh?=
HCC2218 NEHEbWNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1vzemlEPTB;MUmuOUBvVQ>? NVftZo9KW0GQR1XS
TE-6 M{W3O2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYjGR49oUUN3ME2yNE4xQCCwTR?= M1vsb3NCVkeHUh?=
SF539 NGLmdYtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXTWfHJQUUN3ME2yNE43PyCwTR?= MnPuV2FPT0WU
NCI-H446 NIDzWI5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkLJTWM2OD1{MT6xPEBvVQ>? MVjTRW5ITVJ?
IST-MES1 NXjkfFA{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGjpNZdKSzVyPUKyMlc4KG6P NW[zZWEzW0GQR1XS
NCI-H82 M3Xnd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2nyVmlEPTB;MkOuNFIhdk1? NUfRNVdJW0GQR1XS
HCC2157 MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWHJR|UxRTJ|LkGzJI5O NWeyc2tDW0GQR1XS
EW-12 NXnaNVBET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWXJR|UxRTJ|LkG3JI5O NUfa[W5bW0GQR1XS
SIMA NYC4cFdCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYjhTok2UUN3ME2yN{4{QCCwTR?= M121bXNCVkeHUh?=
DOHH-2 NWe5S3VzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFe3VlJKSzVyPUKzMlQ2KG6P NEXOepVUSU6JRWK=
IM-9 MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1ezeGlEPTB;MkOuOVQhdk1? MUjTRW5ITVJ?
EC-GI-10 MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4fJc2lEPTB;MkSuNlMhdk1? M{\ydnNCVkeHUh?=
HDLM-2 MmntS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFzzWZBKSzVyPUK0MlU1KG6P MmewV2FPT0WU
LS-1034 M2XFdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmDKTWM2OD1{NT63OUBvVQ>? NH;lSG5USU6JRWK=
REH MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYLjfWg4UUN3ME2yOk41OSCwTR?= M{Tze3NCVkeHUh?=
LU-165 NYG1S4N[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NF;QNoxKSzVyPUK2MlczKG6P M4XoUXNCVkeHUh?=
NH-12 MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MV\JR|UxRTJ5Lk[3JI5O NXvlWXlRW0GQR1XS
WSU-NHL NXu5bGhFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGLveoZKSzVyPUK4MlM6KG6P NXnJUVFvW0GQR1XS
ECC4 MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUXHZ2VrUUN3ME2yPE44QSCwTR?= MljiV2FPT0WU
OCI-AML2 MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1LVe2lEPTB;MkmuOlkhdk1? M3TV[nNCVkeHUh?=
EW-3 NFfLbm1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2SwO2lEPTB;M{CuOVkhdk1? NXvhPIU5W0GQR1XS
NCI-H526 MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIjH[IFKSzVyPUOyMlU1KG6P MmCwV2FPT0WU
NCI-H719 M4nzfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYD1WlJNUUN3ME2zOE4{OSCwTR?= M1O2RnNCVkeHUh?=
KARPAS-422 NUTmOHpuT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUTvfG04UUN3ME2zOU4xPCCwTR?= M2m0ZXNCVkeHUh?=
SK-MEL-1 MlvPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVHmbZdqUUN3ME2zOU4yPyCwTR?= NG\OXYNUSU6JRWK=
ES3 NUS1W2IyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHPtb2tKSzVyPUO1MlE6KG6P MmnCV2FPT0WU
UACC-812 NG\UelBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1;lfWlEPTB;M{WuOFQhdk1? M3LVSXNCVkeHUh?=
C8166 NX\jfmYzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{HjWmlEPTB;M{WuO{BvVQ>? M2C3VnNCVkeHUh?=
MDA-MB-134-VI MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4DlRWlEPTB;M{WuPFchdk1? Mm\YV2FPT0WU
D-283MED M2TaV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlL4TWM2OD1|Nz63PUBvVQ>? M1jJc3NCVkeHUh?=
SHP-77 Mn;GS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVzJR|UxRTN6LkCzJI5O MmizV2FPT0WU
NCI-H2227 Ml;uS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFLMc|RKSzVyPUSwMlQ6KG6P M2rofHNCVkeHUh?=
SKM-1 M1TyRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHzHOWRKSzVyPUSyMlY{KG6P NFizW3dUSU6JRWK=
L-428 MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M13LZ2lEPTB;NEOuPFYhdk1? M1\yTHNCVkeHUh?=
RPMI-6666 NH;6dG5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGjx[YNKSzVyPUS1Mlg6KG6P NYS2WYRtW0GQR1XS
NCI-H716 NVjPNHUyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIi0UnVKSzVyPUS4MlgyKG6P NYX0Ro5TW0GQR1XS
DMS-79 M371PGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MULJR|UxRTVyLkexJI5O MlPGV2FPT0WU
RS4-11 NVPjXmlWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWLJR|UxRTVyLki4JI5O NEDRbohUSU6JRWK=
NCI-H720 NFW1e2pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHOzXFZKSzVyPUWxMlEyKG6P NH;OdXRUSU6JRWK=
MC-CAR MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoH0TWM2OD13MT61NkBvVQ>? NV;JSGpQW0GQR1XS
TALL-1 NY[1UIk6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXLJR|UxRTV|LkmxJI5O NGOwc4xUSU6JRWK=
NCI-N87 M3S1emdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWPzc2lGUUN3ME21OE4yQCCwTR?= NHjLeVhUSU6JRWK=
P30-OHK NXnTOnkzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYHJR|UxRTV2Lk[xJI5O NFrhU2xUSU6JRWK=
LP-1 NVTJdllTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlT3TWM2OD14MT6yPEBvVQ>? MXfTRW5ITVJ?
YT MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVHJR|UxRTZzLkigcm0> M4DofXNCVkeHUh?=
MRK-nu-1 NGPmfHlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{P3PGlEPTB;NkGuPFIhdk1? MXPTRW5ITVJ?
BT-474 NYS3TnlyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M37ZT2lEPTB;NkWgcm0> MVLTRW5ITVJ?
NCI-H322M NH3jWo1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MX\JR|UxRTZ4LkGxJI5O NEDnSoRUSU6JRWK=
NCI-H128 MlXBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1;Hd2lEPTB;N{SuO|chdk1? NH;EV4xUSU6JRWK=
KMS-12-PE NW\kSo1tT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXzJR|UxRTd4LkK0JI5O NU\CWI95W0GQR1XS
KP-N-YS M{KwfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MonETWM2OD15Nj63OEBvVQ>? M3vqfnNCVkeHUh?=
ALL-PO NH;RO2xIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M13EPGlEPTB;N{euOlYhdk1? NEjVUWVUSU6JRWK=
EW-13 MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVnJR|UxRTd5Lke2JI5O MUnTRW5ITVJ?
EW-11 MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUPNb4syUUN3ME23PE42OiCwTR?= NFfU[FZUSU6JRWK=
SK-N-FI MlHRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmXoTWM2OD16MD6yJI5O M4frd3NCVkeHUh?=
CAL-148 NUjuW2NzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGPuVVhKSzVyPUixMlg1KG6P NVvvRXBQW0GQR1XS
RL NI\KOFBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmTKTWM2OD16Nj6wPUBvVQ>? MnHtV2FPT0WU
AM-38 MlThS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Ml;vTWM2OD16OD6wPEBvVQ>? MVXTRW5ITVJ?
RH-1 NXHXRmRTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVXjfmJFUUN3ME25PU45PSCwTR?= Ml7yV2FPT0WU
NCI-H1770 MlTZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVzBZ|I3UUN3ME2xNFIvPDlibl2= MUHTRW5ITVJ?
SIG-M5 NFriW2FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWfJR|UxRTFyNT6wOkBvVQ>? M160W3NCVkeHUh?=
GR-ST M{jlSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVnJR|UxRTFzMz6zOEBvVQ>? NV\SNJJ6W0GQR1XS
ST486 M3XDTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIj3O2hKSzVyPUGxOE4xPiCwTR?= NHTH[4RUSU6JRWK=
NCI-H1650 NITjOZdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmrPTWM2OD1zMUWuNlkhdk1? NVTHenpsW0GQR1XS
MHH-CALL-2 MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXvnZnBTUUN3ME2xNVUvPyCwTR?= MX3TRW5ITVJ?
BV-173 MmnoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYfJR|UxRTF{Mj63NUBvVQ>? MlHNV2FPT0WU
MC116 NFXSe|ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2m5dGlEPTB;MUS4Mlg2KG6P NHWxc5pUSU6JRWK=
NCI-H524 MlLQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHHLUJFKSzVyPUG1PU4yKG6P M2rFcHNCVkeHUh?=
SCLC-21H MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUK4enp2UUN3ME2xOVkvPDFibl2= NUK4flB4W0GQR1XS
NCI-H1304 M13DVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NF\Wb5RKSzVyPUG2PU4zOSCwTR?= MU\TRW5ITVJ?
NCI-H510A NVn6eJR5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWX5WolKUUN3ME2xPFUvOzdibl2= M13NXnNCVkeHUh?=
NCI-H209 M1L3Vmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mn7nTWM2OD1zOU[uOVIhdk1? M1nacXNCVkeHUh?=
KM-H2 M4[wV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1PXdWlEPTB;MUm3MlA2KG6P NILB[5FUSU6JRWK=
NCI-H1395 NHTuN4hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVXJR|UxRTJzMD6xN{BvVQ>? NI\HSVJUSU6JRWK=
NCI-H1155 NGHUSVFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MX\JR|UxRTJ|MD6zNkBvVQ>? NUTHXopUW0GQR1XS
COR-L279 MlX6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFLSdYNKSzVyPUK1Nk4yPyCwTR?= MXXTRW5ITVJ?
NCI-H1299 NYfLdnp{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3\1N2lEPTB;Mk[xMlcyKG6P MUXTRW5ITVJ?
EW-22 MkL5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFLvWmVKSzVyPUK2N{44PSCwTR?= MomwV2FPT0WU
SK-MEL-2 MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1fMN2lEPTB;MkixMlkhdk1? M{nEUXNCVkeHUh?=
KASUMI-1 MojKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mlz3TWM2OD1{OEOuNFUhdk1? MX\TRW5ITVJ?
NCI-H187 MlGwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1zRZ2lEPTB;Mki3MlA5KG6P MYnTRW5ITVJ?
NCI-H2171 NEHSUItIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHizU3BKSzVyPUK4PE46OiCwTR?= MVPTRW5ITVJ?
LNCaP-Clone-FGC M4Lqc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3PnRWlEPTB;Mkm1MlI3KG6P NGrQN41USU6JRWK=
NCI-H1522 NYjaU|RKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2r4SGlEPTB;M{C3MlA2KG6P NGrC[lFUSU6JRWK=
SCH M1PnOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIS1NG5KSzVyPUOyNk4zOiCwTR?= M1ziW3NCVkeHUh?=
THP-1 M1jFWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFvTTnNKSzVyPUOyNk43KG6P NV[yWolqW0GQR1XS
SNU-C1 NHXQeGtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYfJR|UxRTN4Mj6wPUBvVQ>? NYLlTI9UW0GQR1XS
CA46 NH\xSFNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVnJR|UxRTN5Mz62N{BvVQ>? MlTmV2FPT0WU
NCI-H1963 MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnfJTWM2OD1|OE[uNVkhdk1? NWD5V5NOW0GQR1XS
DEL NX7leGtLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXTqeVhmUUN3ME2zPVEvOjdibl2= MWHTRW5ITVJ?
TUR MkT4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MULJR|UxRTN7Nj62NUBvVQ>? M2TDbXNCVkeHUh?=
NCI-H226 MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYDhTVFkUUN3ME20NFMvOjNibl2= NFnZRXZUSU6JRWK=
COLO-668 MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlXKTWM2OD12MEOuOVchdk1? NGnnXFNUSU6JRWK=
CPC-N NXy2PItLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MV3JR|UxRTRyMz63O{BvVQ>? NXX6do92W0GQR1XS
NCI-H889 MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXnJR|UxRTR4MT65NkBvVQ>? MWnTRW5ITVJ?
J-RT3-T3-5 NHK4VIFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1jWUWlEPTB;NUOyMlU4KG6P NIPOVIJUSU6JRWK=
MSTO-211H M1LOPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYPJR|UxRTV5ND6yOkBvVQ>? NYXweGtrW0GQR1XS
SCC-15 NHvLPWJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYHJR|UxRTZ4Nz60O{BvVQ>? MULTRW5ITVJ?
SUP-T1 MmjmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MV7JR|UxRTZ6Nj6wOEBvVQ>? MlPzV2FPT0WU
DMS-153 M3jCOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoXYTWM2OD15NE[uPFMhdk1? MXTTRW5ITVJ?
MS-1 M1G5Umdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MofsTWM2OD15NUmuOFIhdk1? NVfVRm9mW0GQR1XS
TC-YIK NIG4fpRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnjmTWM2OD15OEGuNFEhdk1? MojGV2FPT0WU
RPMI-8866 M2TxUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3v2[mlEPTB;MUCwOk4zQCEQvF2= MWjTRW5ITVJ?
KY821 M4HoVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGfnOYxKSzVyPUGwN|YvODRizszN Mn;nV2FPT0WU
P31-FUJ NUfvfphHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MU\JR|UxRTFzMUKuO|Uh|ryP MVXTRW5ITVJ?
COLO-824 MnvZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVTJR|UxRTF{NkGuO|gh|ryP NU\rTWIxW0GQR1XS
U-698-M NHTKXVhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWjWUmhSUUN3ME2yNlYzNjF3IN88US=> NIW4[ItUSU6JRWK=
TE-441-T M1XvRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NV3R[oRrUUN3ME2yOVIyNjdizszN NIrYe3lUSU6JRWK=
IMR-5 NGThfVFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2e1OmlEPTB;M{SwPU43OiEQvF2= NXS1VG9OW0GQR1XS
NCI-H1838 M2TwO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlXlTWM2OD12MUi2MlMzKM7:TR?= M2LvOXNCVkeHUh?=

他の多くの細胞株試験データをご覧になる場合はこちらをクリックして下さい

体内試験 The anticancer effects of bortezomib as a single agent have been demonstrated in xenograft models of multiple myeloma, adult T-cell leukemia, lung, breast, prostate, pancreatic, head and neck, and colon cancer, and in melanoma. [2] Oral bortezomib 1.0 mg/ kg daily for 18 days causes tumor growth delays, as well as a decrease in the number of metastases in the Lewis lung cancer model. Bortezomib at a single dose of up to 5 mg/kg significantly decreased the surviving fraction of breast tumor cells. Bortezomib 1.0 mg/kg administrated weekly for 4 weeks reduces tumor growth by 60% in murine xenograft models of prostate cancer. 1.0 mg/kg Bortezomib administration for 4 weeks results in a 72% or 84% reduction in pancreatic cancer murine xenografts growth, as well as an increase in tumor cell apoptosis. 1.0 mg/kg Bortezomib treatment results in significant inhibition of human plasmacytoma xenograft growth, increase in tumor cells apoptosis and overall survival, and a decrease in tumor angiogenesis. [3]

お薦めの試験操作(参考用のみ)

キナーゼ試験:

[4]

+ 展開

Kinetic Methods:

In a typical kinetic run, 2.00 mL of assay buffer (20 mM HEPES, 0.5 mM EDTA, 0.035% SDS, pH 7.8) and Suc-Leu-Leu-Val-Tyr-AMC in DMSO are added to a 3 mL fluorescence cuvette, and the cuvette is placed in the jacketed cell holder of a fluorescence spectrophotometer. Reaction temperature is maintained at 37℃ by a circulating water bath. After the reaction solution has reached thermal equilibrium (5 minutes), 1 μL−10 μL of the stock enzyme solution is added to the cuvette. Reaction progress is monitored by the increase in fluorescence emission at 440 nm (λex= 380 nm) that accompanies cleavage of AMC from peptide-AMC substrates.
細胞試験:

[5]

+ 展開
  • 細胞株: Human multiple myeloma cells line U266
  • 濃度: ~10 μM
  • 反応時間: 2 days
  • 実験の流れ:

    The inhibitory effect of Bortezomib on cell growth is assessed by measuring MTT dye absorbance of the cells. Cells from 48-hour cultures are pulsed with 10 μL of 5 mg/mL MTT to each well for the last 4 hour of 48-hour cultures, followed by 100 μL of isopropanol containing 0.04 N HCl. Absorbance is measured at 570 nm using a spectrophotometer.


    (参考用のみ)
動物試験:

[3]

+ 展開
  • 動物モデル: Human plasmacytoma xenografts RPMI 8226
  • 製剤: Saline
  • 投薬量: 1 mg/kg
  • 投与方法: i.v. twice weekly for 4 weeks, then once weekly
    (参考用のみ)

溶解度 (25°C)

体外 DMSO 76 mg/mL (197.79 mM)
Water Insoluble
Ethanol Insoluble
体内 左から(NMPから)右の順に溶剤を製品に加えます(文献ではなく、Selleckの実験によるデータ):
2% DMSO+30% PEG 300+ddH2O
混合させたのち直ちに使用することを推奨します。
5mg/mL

* 溶解度測定はSelleck技術部門によって行われており、その他文献に示されている溶解度と差異がある可能性がありますが、同一ロットの生産工程で起きる正常な現象ですからご安心ください。

化学情報

分子量 384.24
化学式

C19H25BN4O4

CAS No. 179324-69-7
保管
in solvent
別名 LDP-341, MLM341

便利ツール

モル濃度計算器

モル濃度計算器

求めたい質量、体積または濃度を計算してください。

質量 (g) = 濃度 (mol/L) x 体積 (L) x 分子量 (g/mol)

モル濃度計算器方程式

  • 質量
    濃度
    体積
    分子量

*貯蔵液を準備するとき、常に、オンであるとわかる製品のバッチに特有の分子量を使って、を通してラベルとMSDS/COA(製品ページで利用可能な)。

希釈計算器

希釈計算器

貯蔵液を準備するために必要な希釈率を計算してください。Selleck希釈計算器は、以下の方程式に基づきます:

開始濃度 x 開始体積 = 最終濃度 x 最終体積

希釈の計算式

この方程式は、一般に略語を使われます:C1V1 = C2V2 ( 入力 出力 )

  • C1
    V1
    C2
    V2

常に貯蔵液を準備するとき、小びんラベルとMSDS/COA(オンラインで利用できる)で見つかる製品のバッチに特有の分子量を使ってください。

連続希釈計算器方程式

  • 連続希釈剤

  • 計算結果

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
分子量計算器

分子量计算器

そのモル質量と元素組成を計算するために、合成物の化学式を入力してください:

総分子量:g/mol

チップス: 化学式は大文字と小文字の区別ができます。C10H16N2O2 c10h16n2o2

モル濃度計算器

質量 濃度 体積 分子量

臨床試験

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT03136146 Recruiting Hematopoietic/Lymphoid Cancer|Acute Lymphoblastic Leukemia|Lymphoblastic Lymphoma|Burkitt Leukemia/Lymphoma M.D. Anderson Cancer Center August 9 2017 Phase 2
NCT02951819 Active not recruiting Multiple Myeloma Janssen Scientific Affairs LLC November 9 2016 Phase 2
NCT01453101 Active not recruiting Multiple Myeloma Hackensack Meridian Health June 9 2010 Phase 2
NCT01449344 Active not recruiting Mantle Cell Lymphoma Prof. Dr. M. Dreyling (co-chairman)|Klinikum der Universitaet Muenchen Grosshadern|ClinAssess GmbH|GELARC Service de Pharmacovigilance Pierre Benite|European Mantle Cell Lymphoma Network May 9 2009 Phase 3
NCT00703664 Completed Recurrent Mantle Cell Lymphoma|Recurrent Non-Hodgkin Lymphoma National Cancer Institute (NCI) July 9 2008 Phase 2
NCT01965977 Recruiting Diffuse Large B Cell Lymphoma Samsung Medical Center|Janssen LP April 8 2015 Phase 2

技術サポート

ストックの作り方、阻害剤の保管方法、細胞実験や動物実験の際に注意すべき点など、製品を取扱う時に問い合わせが多かった質問に対しては取扱説明書でお答えしています。

Handling Instructions

他に質問がある場合は、お気軽にお問い合わせください。

  • * 必須

よくある質問(FAQ)

  • 質問1:

    On your website, it is mentioned that Bortezomib should be prepared at a concentration of 5 mg/ml in 2% DMSO/30% PEG300/ddH2O for in vivo use. But on the product sheet we received with the compound, it is mentioned: 5mg/ml in 0.5% methylcellulose, 0.2% tween 80. So which is the correct preparation buffer?

  • 回答:

    S1013 Bortezomib in 2% DMSO+30% PEG 300+ddH2O at 5 mg/ml is a clear solution, and it in 0.5% methylcellulose+0.2% Tween 80 is a suspension. Please choose the suitable vehicle according to your administration route. When you prepare the clear solution, please dissolve Bortezomib in DMSO first, make sure it dissolves well, warm it up to 45 degree and/or sonicate if necessary, then add PEG, mix well, and finally add water.

Proteasomeシグナル伝達経路

Proteasome Inhibitors with Unique Features

相関Proteasome製品

Tags: Bortezomib (PS-341)を買う | Bortezomib (PS-341) ic50 | Bortezomib (PS-341)供給者 | Bortezomib (PS-341)を購入する | Bortezomib (PS-341)費用 | Bortezomib (PS-341)生産者 | オーダーBortezomib (PS-341) | Bortezomib (PS-341)化学構造 | Bortezomib (PS-341)分子量 | Bortezomib (PS-341)代理店
×
細胞株 試験類型 濃度 培養時間 溶剤類型 活性叙述 PMID